CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 9,300 Shares

CryoPort, Inc. (NASDAQ:CYRXGet Free Report) CFO Robert Stefanovich sold 9,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the completion of the sale, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This trade represents a 4.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

CryoPort Stock Performance

NASDAQ CYRX opened at $8.97 on Friday. The company’s 50 day moving average is $7.63 and its 200-day moving average is $6.65. CryoPort, Inc. has a 12-month low of $4.58 and a 12-month high of $9.48. The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39. The firm has a market cap of $449.13 million, a P/E ratio of 6.74 and a beta of 1.88.

CryoPort (NASDAQ:CYRXGet Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The business had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Sell-side analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CYRX shares. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of CryoPort in a research report on Thursday, May 8th. KeyCorp upgraded CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price target on the stock in a research report on Wednesday, August 6th. Leerink Partnrs upgraded CryoPort from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 6th. BTIG Research decreased their price target on CryoPort from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, July 7th. Finally, Morgan Stanley decreased their price target on CryoPort from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Monday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $12.00.

Read Our Latest Research Report on CryoPort

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently bought and sold shares of CYRX. JPMorgan Chase & Co. boosted its stake in CryoPort by 10.8% in the fourth quarter. JPMorgan Chase & Co. now owns 338,315 shares of the company’s stock worth $2,632,000 after buying an additional 33,078 shares in the last quarter. Wells Fargo & Company MN boosted its stake in CryoPort by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 28,767 shares of the company’s stock worth $224,000 after buying an additional 6,533 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in CryoPort by 135.5% in the fourth quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock worth $100,000 after buying an additional 7,407 shares in the last quarter. Invesco Ltd. boosted its stake in CryoPort by 11.6% in the fourth quarter. Invesco Ltd. now owns 51,803 shares of the company’s stock worth $403,000 after buying an additional 5,364 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in CryoPort in the fourth quarter worth approximately $194,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

(Get Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Read More

Insider Buying and Selling by Quarter for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.